Medicare Enrolled
Dr. Anna Niewiarowska, M.D.
Hematology & Oncology · Bethlehem, PA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Niewiarowska from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Niewiarowska?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Niewiarowska
Dr. Anna Niewiarowska is a hematology & oncology specialist in Bethlehem, PA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Niewiarowska performed 10,934 Medicare services across 969 unique beneficiaries.
Between the years covered by Open Payments, Dr. Niewiarowska received a total of $6,055 from 54 pharmaceutical and/or device companies across 159 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Niewiarowska is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 18% volume in PA
$6,055 industry payments
Medicare Practice Summary
Medicare Utilization ↗10,934
Medicare services
Top 18% in PA for hematology & oncology
969
Unique beneficiaries
$15
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~575 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 3,503 | $18 | $45 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,511 | $0 | $2 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
732 | $7 | $23 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
663 | $10 | $31 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
651 | $11 | $70 |
| Magnesium level test A blood test to measure the amount of magnesium in your body. This helps check for magnesium deficiency or excess. |
647 | $6 | $31 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
617 | $6 | $26 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
351 | $10 | $52 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
193 | $1 | $31 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
189 | $90 | $300 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
188 | $1 | $3 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
174 | $20 | $90 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
170 | $9 | $50 |
| Carcinoembryonic antigen (CEA) level test A blood test that measures the level of carcinoembryonic antigen (CEA) protein. This test is used to monitor certain types of cancer. |
165 | $17 | $46 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
160 | $123 | $310 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
153 | $20 | $110 |
| Phosphate level test A blood test that measures the amount of phosphate in your body. Phosphate is a mineral that helps keep bones and teeth strong. |
125 | $4 | $16 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 114 | $18 | $41 |
| Vitamin D level test A blood test to measure the amount of Vitamin D-3 in your body. |
104 | $28 | $75 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
97 | $90 | $210 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
95 | $45 | $160 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
80 | $13 | $31 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
64 | $60 | $150 |
| Vitamin B-12 level test A blood test that measures the amount of vitamin B-12 in your body. |
59 | $15 | $51 |
| Uric acid level test A blood test that measures the level of uric acid in your body. Uric acid is a waste product formed when the body breaks down purines. |
43 | $4 | $16 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
43 | $24 | $128 |
| Thyroid stimulating hormone (TSH) test A blood test that measures the level of thyroid stimulating hormone to evaluate thyroid function. |
32 | $16 | $41 |
| New patient office visit, complex (60-74 min) | 11 | $152 | $465 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
4.6% high complexity
58.1% medium
37.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$6,055
Total received (2018-2024)
Avg $865/year across 7 years
Top 29% in PA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
54
Companies
159
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,072 (50.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$2,984 (49.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,492
2023
$756
2022
$372
2021
$492
2020
$232
2019
$49
2018
$2,663
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$240
Daiichi Sankyo Inc.
$145
Merck Sharp & Dohme LLC
$113
Novartis Pharmaceuticals Corporation
$81
E.R. Squibb & Sons, L.L.C.
$66
GlaxoSmithKline, LLC.
$64
EMD Serono, Inc.
$58
Incyte Corporation
$57
Tempus AI, Inc
$56
Genentech USA, Inc.
$54
ABBVIE INC.
$49
SERVIER PHARMACEUTICALS LLC
$45
PharmaEssentia USA Corporation
$44
Gilead Sciences, Inc.
$43
SpringWorks Therapeutics, Inc.
$39
Astellas Pharma US Inc
$39
Celltrion USA Inc.
$31
Novocure Inc.
$31
Janssen Biotech, Inc.
$27
Genmab U.S., Inc.
$26
PUMA BIOTECHNOLOGY, INC.
$25
Takeda Pharmaceuticals U.S.A., Inc.
$24
SOBI, INC
$24
Mirati Therapeutics, Inc.
$21
Fresenius Kabi USA, LLC
$21
Rigel Pharmaceuticals, Inc.
$17
Ipsen Biopharmaceuticals, Inc
$17
Spectrum Pharmaceuticals Inc.
$16
Kite Pharma, Inc.
$15
Top 3 companies account for 33.4% of 2024 payments
All-time payments by company (2018-2024) ›
Exelixis Inc.
$2,644
Novartis Pharmaceuticals Corporation
$424
Daiichi Sankyo Inc.
$268
PFIZER INC.
$254
E.R. Squibb & Sons, L.L.C.
$184
Incyte Corporation
$175
Janssen Biotech, Inc.
$149
Merck Sharp & Dohme LLC
$147
Gilead Sciences, Inc.
$129
Celgene Corporation
$98
AstraZeneca Pharmaceuticals LP
$82
Amgen Inc.
$79
EMD Serono, Inc.
$75
Genentech USA, Inc.
$74
GlaxoSmithKline, LLC.
$64
Stemline Therapeutics Inc.
$63
MorphoSys, US Inc.
$63
Tempus AI, Inc
$56
Epizyme, Inc.,
$51
Acrotech Biopharma Inc.
$51
ABBVIE INC.
$49
Kite Pharma, Inc.
$47
Seagen Inc.
$45
SERVIER PHARMACEUTICALS LLC
$45
PharmaEssentia USA Corporation
$44
Bayer Healthcare Pharmaceuticals Inc.
$40
SpringWorks Therapeutics, Inc.
$39
AbbVie Inc.
$39
Astellas Pharma US Inc
$39
JAZZ PHARMACEUTICALS INC.
$39
GENZYME CORPORATION
$31
Celltrion USA Inc.
$31
Novocure Inc.
$31
Genmab U.S., Inc.
$26
PUMA BIOTECHNOLOGY, INC.
$25
Takeda Pharmaceuticals U.S.A., Inc.
$24
SOBI, INC
$24
ARRAY BIOPHARMA INC
$23
AVEO Pharmaceuticals, Inc.
$22
Coherus Biosciences Inc.
$22
Organon LLC
$22
Sandoz Inc.
$22
Mirati Therapeutics, Inc.
$21
Fresenius Kabi USA, LLC
$21
CTI BioPharma Corp.
$20
Dova Pharmaceuticals
$19
Karyopharm Therapeutics Inc.
$18
Rigel Pharmaceuticals, Inc.
$17
Ipsen Biopharmaceuticals, Inc
$17
Spectrum Pharmaceuticals Inc.
$16
Global Blood Therapeutics, Inc.
$13
Octapharma USA, Inc.
$13
Horizon Therapeutics plc
$13
Heron Therapeutics, Inc.
$6
Top 3 companies account for 55.1% of all-time payments
Associated products mentioned in payments ›
ACTIMMUNE · BELEODAQ · BESREMI · BRAFTOVI · Bavencio · CINVANTI · CREON · Cabometyx · Columvi · DARZALEX · Doptelet · ELZONRIS · ENHERTU · ERLEADA · Enhertu · Epkinly · FOTIVDA · Fabhalta · INJECTAFER · INLYTA · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · LUMAKRAS · LYNPARZA · MEKINIST · MONJUVI · NINLARO · Nubeqa · OCTAGAM · OGSIVEO · OJJAARA · ONTRUZANT · ONUREG · OPDIVO · OPDUALAG · OXBRYTA · Onivyde · Optune · Orserdu · PADCEV · PIQRAY · PROMACTA · Pomalyst · Prolia · REMICADE · ROLVEDON · Rezlidhia · SCEMBLIX · Stimufend · TABRECTA · TAGRISSO · TAZVERIK · TECENTRIQ · TUKYSA · Tibsovo · Trodelvy · Udenyca · VEGZELMA · VENCLEXTA · VONJO · Venclexta · Vonjo · XGEVA · XPOVIO · Xospata · Xtandi · Yescarta · ZARXIO · ZEPOSIA · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (51%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
51
Per 100K population
16.1
County median income
$86,687
Nearest hospital
ST LUKES HOSPITAL BETHLEHEM
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Niewiarowska is a mixed practice specialist, with above-average Medicare volume (top 18% in PA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Niewiarowska experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Niewiarowska performed 3,503 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Niewiarowska receive payments from pharmaceutical companies?
Yes. Dr. Niewiarowska received a total of $6,055 from 54 companies across 159 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Niewiarowska's costs compare to other hematology & oncology specialists in Bethlehem?
Dr. Niewiarowska's average Medicare payment per service is $15. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Niewiarowska) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Bethlehem
Browse hematology & oncology specialists in Bethlehem ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in PA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in PA
Which PA hematology & oncology specialists receive the most from drug and device companies.
By company
Exelixis Inc. Payments to Doctors
See all physicians who received payments from Exelixis Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Daiichi Sankyo Inc. Payments to Doctors
See all physicians who received payments from Daiichi Sankyo Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology